ReviewVeterinary medicine international2026
Dosage of Pimobendan in Domestic Cats.
Review in Veterinary medicine international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Available evidence suggests that pimobendan may provide clinical benefits in the treatment of heart diseases in cats. However, its dosage is based on studies conducted in dogs, raising concerns due to differences in plasma concentrations between species. Review Question: What is the dosage of pimobendan used in domestic cats, either healthy or with heart disease? Methods: Searches in the PubMed, Web of Science, Scopus, and ScienceDirect databases were conducted between October and November 2024, a period corresponding to the execution of the search strategy. Full-text articles were included without restrictions regarding language, country, or year of publication, while gray literature was excluded. Results: Out of 371 articles screened, 15 were excluded due to duplication or lack of relevance, resulting in 10 studies being included in the final review. Pimobendan dosages ranged from 0.125 mg/kg to 0.5 mg/kg, with oral administration being predominant, typically every 12 h. Some studies used single doses to evaluate the drug's pharmacodynamics. Beneficial effects observed included improved cardiac output, enhanced left ventricular function, and reduced risk of thrombi. Common adverse effects were anorexia, vomiting, lethargy, hypotension, and arrhythmias, particularly tachycardia (4/10). The studies showed some risk of bias, such as lack of detailed information on sex, weight, and adverse effects in cats, heterogeneity in study populations, variability in pimobendan doses, and insufficient control of cardiac disease conditions. Conclusion and Clinical Relevance: Pimobendan was well tolerated in cats, with only isolated and no clinically relevant adverse effects reported, at doses ranging from 0.24 to 0.5 mg/kg or 1.25 mg/cat, with oral administration every 12 h being the recommended regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.